- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05454189
Safety of Extending The Routine Flushing Of Implanted Port Devices From 4 Weeks To 12
December 29, 2023 updated by: Essentia Health
A Prospective, Randomized Study To Evaluate The Safety of Extending The Routine Flushing Of Implanted Port Devices From 4 Weeks To 12 Weeks
Implanted port devices (IPD) play an essential role in the safe administration of cancer treatments by providing a device to safely administer caustic chemotherapy agents.
The current recommended frequency of flushing the IPD per manufacturers guidelines is every 4-6 weeks.
The purpose of this study is to find out if extending IPD flushes to every 12 weeks is safe and if it is just as effective as every 4 week flushing.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
After being informed about the study and potential risks, all participants giving written informed consent will complete port specific histories, assessments and questionnaires within 14 days prior to registration.
Eligible, consented participants will be registered to the study and randomized to receive either IPD standard maintenance flushes and port assessments every 4 weeks or every 12 weeks for an initial 12 week interval.
If study participants agree to the continuation portion of the study, they will continue to receive either IPD standard maintenance flushes and port assessments every 4 weeks or every 12 weeks for up to an additional three 12 week cycles.
Study Type
Interventional
Enrollment (Estimated)
400
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Bret Friday, MD, PhD
- Phone Number: 218-786-3625
- Email: bret.friday@essentiahealth.org
Study Contact Backup
- Name: Tammie Mlodozyniec
- Phone Number: 218-786-1018
- Email: tammie.mlodozyniec@essentiahealth.org
Study Locations
-
-
Minnesota
-
Albert Lea, Minnesota, United States, 56007
- Recruiting
- Mayo Clinic Health System - Albert Lea
-
Contact:
- Mina Hanna, MD
- Phone Number: 612-624-2620
- Email: ccinfo@umn.edu
-
Brainerd, Minnesota, United States, 56401
- Recruiting
- Essentia Health St. Joseph's Medical Center
-
Deer River, Minnesota, United States, 56636
- Recruiting
- Essentia Health Deer River Clinic
-
Contact:
- Tammie Mlodozyniec
-
Detroit Lakes, Minnesota, United States, 56501
- Recruiting
- Essentia Health St Mary's Detroit Lakes Clinic
-
Contact:
- Tammie Mlodozyniec
-
Duluth, Minnesota, United States, 55805
- Recruiting
- Essentia Health Duluth Clinic
-
Principal Investigator:
- Bret Friday, MD, PhD
-
Contact:
- Tammie Mlodozyniec
- Phone Number: 218-786-1018
- Email: tammie.mlodozyniec@essentiahealth.org
-
Fosston, Minnesota, United States, 56542
- Recruiting
- Essentia Health Fosston
-
Contact:
- Tammie Mlodozyniec
-
Grand Rapids, Minnesota, United States, 55744
- Recruiting
- Fairview Grand Itasca Clinic & Hospital
-
Contact:
- Anastas Provatas
- Phone Number: 612-624-2620
- Email: ccinfo@umn.edu
-
Hibbing, Minnesota, United States, 55746
- Recruiting
- Essentia Health Hibbing Clinic
-
Contact:
- Tammie Mlodozyniec
-
Hibbing, Minnesota, United States, 55746
- Recruiting
- Fairview Range Medical Center
-
Contact:
- Anastas Provatas
- Phone Number: 612-624-2620
- Email: ccinfo@umn.edu
-
Mankato, Minnesota, United States, 56001
- Recruiting
- Mayo Clinic Health System - Mankato
-
Contact:
- Stephan Thome
- Phone Number: 612-624-2620
- Email: ccinfo@umn.edu
-
Monticello, Minnesota, United States, 55362
- Recruiting
- Monticello Cancer Center
-
Contact:
- Yan Ji, MD
- Phone Number: 612-624-2620
- Email: ccinfo@umn.edu
-
Park Rapids, Minnesota, United States, 56470
- Recruiting
- Essentia Health Park Rapids
-
Contact:
- Tammie Mlodozyniec
-
Princeton, Minnesota, United States, 55371
- Recruiting
- Fairview Northland Medical Center
-
Contact:
- Anastas Provatas
- Phone Number: 612-624-2620
- Email: ccinfo@umn.edu
-
Sandstone, Minnesota, United States, 55072
- Recruiting
- Essentia Health Sandstone
-
Contact:
- Tammie Mlodozyniec
-
Virginia, Minnesota, United States, 55792
- Recruiting
- Essentia Health Virginia Clinic
-
Contact:
- Tammie Mlodozyniec
-
Worthington, Minnesota, United States, 56187
- Recruiting
- Sanford Worthington Medical Center
-
Contact:
- Jonathan Bleeker
- Phone Number: 612-624-2620
- Email: ccinfo@umn.edu
-
-
North Dakota
-
Fargo, North Dakota, United States, 58103
- Recruiting
- Essentia Health Fargo
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Hematology/Oncology patients ≥ 18 years old with an Implanted Port Device.
- No planned clinical visits for at least 12 weeks.
- No planned need to access Implanted Port Device within next 12 weeks outside of routine flushing. Potential reasons to access can include but are not limited to lab draw, infusion, IV contrast.
- No planned removal of IPD within 12 weeks of registration.
- No Deep Vein Thrombosis or significant Implanted Port Device complication within ≤ 4 weeks of registration.
- Patient Implanted Port Device with documented blood return ≤ 14 days of registration.
- Ability to read and speak English.
- Able to give informed consent.
Exclusion Criteria:
- Allergy to heparin
- Vulnerable populations: pregnant women, prisoners, mentally handicapped.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 4-week IPD Flushing Schedule
IPD standard maintenance flushes and port assessments every 4 weeks.
|
IPD flush every 4 weeks
|
Experimental: 12-week IPD Flushing Schedule
IPD standard maintenance flushes and port assessments every 12 weeks.
|
IPD flush every 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of IPD patency
Time Frame: 12 weeks post randomization
|
IPD patency without major complication
|
12 weeks post randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Long-term rate of IPD patency in scheduled 4-week versus 12-week IPD flushes at 24,36 and 48 weeks post randomization.
Time Frame: Up to 48 weeks post randomization
|
Rate of IPD patency during long term follow-up
|
Up to 48 weeks post randomization
|
Difference in complication rates in scheduled 4-week versus 12-week IPD flushes at 12, 24,36 and 48 weeks post randomization.
Time Frame: Up to 48 weeks post randomization
|
Differences in specific complications such as occlusion, infection, mechanical as assessed by port assessments and adverse events
|
Up to 48 weeks post randomization
|
Difference in healthcare and patient cost in scheduled 4-week versus 12-week IPD flushes
Time Frame: Up to 48 weeks post randomization
|
Determine healthcare and patient cost differences based documented participant charges and participant reported responses to a 8 question financial burden questionnaire.
The questionnaire gathers demographic information about employment, method of payment, estimated costs, education level, and smoking status.
|
Up to 48 weeks post randomization
|
Change in Participant Quality of Life and Satisfaction in Scheduled 4-week versus 12 week IPD flushes
Time Frame: Up to 48 weeks post randomization
|
Compare participant quality of life and satisfaction over time and between 4-week versus 12-week IPD flushes as assessed by participant responses to 7 question quality of life questionnaire.
The questionnaire is specific to IPD flushing and uses a 5 point likert scale.
|
Up to 48 weeks post randomization
|
Impact of smoking, participant age, IPD age, and concomitant medications on complication rates in scheduled 4-week versus 12 week IPD flushes.
Time Frame: Up to 48 weeks post randomization
|
Impact of smoking, participant age, IPD age, and concomitant medications on complication rates as assessed by participant response smoking status and port assessments and adverse events
|
Up to 48 weeks post randomization
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Bret Friday, MD, PhD, Essentia Health
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 11, 2022
Primary Completion (Estimated)
October 1, 2024
Study Completion (Estimated)
October 1, 2024
Study Registration Dates
First Submitted
June 24, 2022
First Submitted That Met QC Criteria
July 8, 2022
First Posted (Actual)
July 12, 2022
Study Record Updates
Last Update Posted (Estimated)
January 3, 2024
Last Update Submitted That Met QC Criteria
December 29, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MNCCTN024
- EH21C1 (Other Identifier: Essentia Health)
- EH22738 (Other Identifier: Essentia Health)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The study protocol, statistical plan and consent form will be available on request.
Data will be available on aggregate level; data will be deidentified, the full dataset and statistical code will be available upon request
IPD Sharing Time Frame
6 months after study completion and for 36 months
IPD Sharing Access Criteria
A full description of the intended use of the data must be sent to the Project Direct for review and approval.
Participant consent for data sharing is conditioned and new ethics approval may be required.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Maintenance of Implanted Port Devices
-
Rambam Health Care CampusUnknownDurability of Implanted Intravascular Stents | Hemodynamic Effect of Implanted Intravascular Stents
-
Abbott Medical DevicesCompletedAdverse Effect of MRI on an Implanted Pacemaker Lead | Adverse Effect of MRI on an Implanted PacemakerUnited States, Netherlands, Australia, Belgium, Finland
-
University of Sao PauloCompletedInfluence of Low-level Laser Therapy on Stability and Displacement of Orthodontic Miniscrew ImplantsDisplacement of Other Bone Devices, Implants and Grafts | Mechanical Complication of Other Bone Devices, Implants and Grafts
-
Cairo UniversityActive, not recruitingTo Try to Eliminate Frequencies of Insertions in Order to Arrive to Adequate Size of Implanted Penile ProsthesisEgypt
-
Sohag UniversityNot yet recruitingChange of Tempromandibular Joint Function With Supra Glottic Airway Devices
-
Jonkoping UniversityEnrolling by invitationWheelchairs | Balance | Posture | Self-Help Devices | Sitting Position | Limits of StabilitySweden
-
University of Maryland, BaltimoreCompletedRobotic Surgery | Renal Transplant Donor of Left Kidney | Donor Nephrectomy | Single-portUnited States
-
Deutsches Herzzentrum MuenchenCompletedElectrode Malfunction | Infections of Cardiac Electronic Implantable DevicesGermany
-
SanofiCompletedMaintenance of Smoking CessationUnited States, Canada, Australia
-
Universitair Ziekenhuis BrusselCompletedHealth Care Utilization | Availability of the Different Types of Anesthesia Neuromuscular Monitoring Devices Throughout European Hospitals | Medical Device Availability | Medical Staff AvailabilityBelgium
Clinical Trials on Standard IPD Flush Schedule
-
University of LouisvilleJames Graham Brown Cancer CenterCompletedComplication of CatheterUnited States
-
Universidade Federal de GoiasUnknown
-
Children's Mercy Hospital Kansas CityCompletedAbdominal Abscess | Tissue Plasminogen ActivatorUnited States
-
NRZ Magdeburg Median Kliniken GmbH & CoCompleted
-
University Health Network, TorontoUnknownThoracic Aortic Aneurysm | Stroke, Complication | Aortic Stenosis SymptomaticCanada
-
Hennepin Healthcare Research InstituteCompletedRespiratory Failure
-
Fundación Pública Andaluza Progreso y SaludCompletedChronic Obstructive Pulmonary Disease (COPD)Spain
-
Ontario Clinical Oncology Group (OCOG)Canadian Institutes of Health Research (CIHR); Trans Tasman Radiation Oncology...Completed
-
Ontario Clinical Oncology Group (OCOG)NCIC Clinical Trials GroupCompleted